NEJM published phase 2b clinical trial results demonstrating efficacy of COVID-19 vaccine against B.1.351 variant
On May 5, 2021, Novavax announced the publication of results from the initial primary analysis of a Phase…
-
-
Pfizer and BioNTech received Health Canada authorization of COVID-19 vaccine in adolescents
On May 5, 2021, Pfizer and BioNTech announced that Health Canada had expanded the Interim Order authorization for…
-
Moderna announced expansion of its manufacturing technology center in Massachusetts
On May 4, 2021, Moderna announced an expansion of the Moderna Technology Center (MTC) in Norwood, MA including…
-
HDT Bio, Gennova Biopharma announced volunteers dosed in phase I/II trials of COVID-19 RNA vaccine in India
On May 4, 2021, HDT Bio announced that its development partner in India, Gennova Biopharmaceuticals, had begun dosing…
-
WHO welcomed Sweden’s announcement to share COVID-19 vaccine doses with COVAX
On May 3, 2021, the World Health Organization (WHO) welcomed the Government of Swedenﾒs announcement to share 1…
-
Data from Vaxart oral COVID-19 vaccine phase I study suggested broad cross-reactivity against Coronaviruses
On May 3, 2021, Vaxart announced that new data obtained from its Phase I COVID-19 trial added to…
-
Moderna announced supply agreement with Gavi for up to 500 million doses of COVID-19 Vaccine Moderna for COVAX
On May 3, 2021, Moderna announced an agreement with Gavi, the Vaccine Alliance to supply up to 500…
-
Novavax initiated pediatric expansion for phase 3 clinical trial of COVID-19 vaccine
On May 3, 2021, Novavax announced that it had initiated a pediatric expansion of its Phase 3 clinical…
-
Gavi signed agreement with Moderna to secure doses on behalf of COVAX Facility
On May 3, 2021, Gavi, the Vaccine Alliance, that it had signed an advance purchase agreement with Moderna…
-
Moderna announced Emergency Use listing granted by the WHO for its COVID-19 vaccine
On Apr. 30, 2021, Moderna announced that the World Health Organization (WHO) had issued Emergency Use Listing (EUL)…
-
Pfizer and BioNTech submitted request to expand conditional marketing authorization of COMIRNATY in EU to adolescents
On Apr. 29, 2021, Pfizer and BioNTech announced they had submitted a variation to the Conditional Marketing Authorization…
-
Lonza and Moderna entered agreement to double drug substance production for COVID-19 vaccine in Visp
On Apr. 29, 2021, Lonza announced the expansion of its collaboration with Moderna to manufacture the drug substance…
-
NIH announced investment of $29 million to address COVID-19 disparities
On Apr. 29, 2021, the National Institutes of Health announced it was funding $29 million in additional grants…
-
Moderna announced an increased global supply for COVID-19 vaccine to up to 3 billion doses in 2022
On Apr. 29, 2021, Moderna announced it was making new funding commitments to increase supply at its owned…
-
VBI Vaccines announced publication of Challenge Study Data of its eVLP vaccine candidate against COVID-19
On Apr. 28, 2021, VBI Vaccines announced that preclinical data of VBIﾒs enveloped virus-like particle (eVLP) vaccine candidate,…
-
CDC | COVID-19 | Infectious Disease | Vaccine
Fully vaccinated adults 65 and older are 94% less likely to be hospitalized with COVID-19
On Apr. 28, 2021, the Centers for Disease Control and Prevention (CDC) announced that both mRNA COVID-19 vaccines…
-
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | Life Science History | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | USDA | Vaccine | WHO
COVID-19 science and reason
COVID-19 and it’s naysayers are attacking Science and Reason. The defenders must suffer the slings and arrows from…
-
Biotechnology | COVID-19 | Disease | Infectious Disease | Oncology | Rare Disease | Therapeutics | Vaccine
Moderna announced agreement with Sanofi for manufacturing of Moderna COVID-19 Vaccine in the U.S.
On Apr. 26, 2021, Moderna announced that it had entered into an agreement with Sanofi for fill/finish sterile…
-
COVID-19 infections survey revealed significant reductions in COVID-19 infections with single dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccine
On Apr. 23, 2021, University of Oxford data from the COVID-19 Infection Survey was the first to show…
-
INOVIO planned for ex-US global phase 3 trial for INO-4800
On Apr. 23, 2021, Inovio Pharma announced that it was planning for a predominantly ex-U.S. Phase 3 trial…
-
The WHO announced continued review of emerging evidence on AstraZeneca COVID-19 vaccines
On Apr. 22, 2021, the Strategic Advisory Group of Experts (SAGE) on Immunization annouced updated interim guidance on…
-
Valneva initiated pivotal phase 3 clinical trial for inactivated, COVID-19 vaccine using Dynavax’s CpG 1018ﾙ adjuvant
On Apr. 21, 2021, Dynavax Technologies announced Valneva had initiated a pivotal Phase 3 clinical trial for its…
-
RTS,S malaria vaccine reached more than 650 000 children in Ghana, Kenya and Malawi through pilot programme
On Apr. 20, 2021, the World Health Organization (WHO) announced that two years on from the launch of…
-
Johnson & Johnson COVID-19 vaccine roll-out resumed in Europe following EMA review
On Apr. 20, 2021, Johnson & Johnson announced that the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee had…
-
Pfizer and BioNTech supply the European Union with 100 million additional doses of COMIRNATY
On Apr. 19, 2021, Pfizer and BioNTech announced supplying an additional 100 million doses of COMIRNATY, the companies…
-
Risk of rare blood clotting higher for COVID-19 than for vaccines
On Apr. 15, 2021, researchers at the University of Oxford reported that the risk of the rare blood…
-
NIH funded new influenza research network
On Apr. 15, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had established a…
-
INOVIO’s COVID-19 vaccine candidate provided broad cross-reactive immune responses In humans against variants
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
-
Merck discontinued development of MK-7110 for COVID-19
On Apr. 15, 2021, Merck announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the…
-
AstraZeneca announced update on the safety of COVID-19 vaccine
On Apr. 14, 2021, following concern raised around thrombotic events, AstraZeneca offered its reassurance on the safety of…
